Research ArticleClinical Studies
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer
KOSUKE TAKAHASHI, YOSHIAKI OSAKA, YOSHIHIRO OTA, TAKAFUMI WATANABE, KENICHI IWASAKI, SHINGO TACHIBANA, YUICHI NAGAKAWA, KENJI KATSUMATA and AKIHIKO TSUCHIDA
Anticancer Research May 2020, 40 (5) 2827-2832; DOI: https://doi.org/10.21873/anticanres.14256
KOSUKE TAKAHASHI
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
YOSHIAKI OSAKA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
YOSHIHIRO OTA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
TAKAFUMI WATANABE
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
KENICHI IWASAKI
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
SHINGO TACHIBANA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
YUICHI NAGAKAWA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
KENJI KATSUMATA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
AKIHIKO TSUCHIDA
Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan
In this issue
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer
KOSUKE TAKAHASHI, YOSHIAKI OSAKA, YOSHIHIRO OTA, TAKAFUMI WATANABE, KENICHI IWASAKI, SHINGO TACHIBANA, YUICHI NAGAKAWA, KENJI KATSUMATA, AKIHIKO TSUCHIDA
Anticancer Research May 2020, 40 (5) 2827-2832; DOI: 10.21873/anticanres.14256
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer
KOSUKE TAKAHASHI, YOSHIAKI OSAKA, YOSHIHIRO OTA, TAKAFUMI WATANABE, KENICHI IWASAKI, SHINGO TACHIBANA, YUICHI NAGAKAWA, KENJI KATSUMATA, AKIHIKO TSUCHIDA
Anticancer Research May 2020, 40 (5) 2827-2832; DOI: 10.21873/anticanres.14256
Jump to section
Related Articles
- No related articles found.
Cited By...
- Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer
- Sleep Problems Prior to Radio-chemotherapy in Patients With Locally Advanced Cancer of the Esophagus or the Esophagogastric Junction
- Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) vs. Cisplatin and 5-Fluorouracil (CF-RT) for Patients With Unresectable Locally Advanced Esophageal Cancer in a Real-world Clinical Setting